Revance Therapeutics – Commercial Fill/Finish Services Agreement (May 9th, 2017)
This Technology Transfer, Validation and Commercial Fill/Finish Services Agreement (the "Agreement") is entered into as of the 14th day of March, 2017 ("Effective Date") by and between Revance Therapeutics, Inc., a Delaware corporation, having its principal place of business at 7555 Gateway Blvd., Newark, CA 94560 ("Client"), and Ajinomoto Althea, Inc., a Delaware corporation, with a place of business located at 11040 Roselle Street, San Diego, CA 92121 ("Althea");
Revance Therapeutics – Revance Therapeutics, Inc. 2017 Management Bonus Program (February 28th, 2017)
On January 26, 2017, the Compensation Committee of the Board of Directors of Revance Therapeutics, Inc. (the "Company") approved the Company's 2017 corporate objectives, weighted for purposes of determining bonuses, if any, for the Company's executive officers with respect to performance for fiscal year 2017 (the "2017 Bonus Program").
Revance Therapeutics – Revance Therapeutics, Inc. Common Stock Sales Agreement (March 7th, 2016)